$Cellectar Biosciences Inc.(CLRB)$StreetInsiderCellectar Biosciences (CLRB) Announces Positive Prelim. Results for CLR 1602 in Tumor TargetingJune 15, 2016 8:34 AM Cellectar Biosciences, Inc. (Nasdaq: CLRB) announces the results of a preliminary tumor-targeting study that shows its prototype paclitaxel chemotherapeutic conjugate, CLR 1602, may be up to 30 times more tumor selective in comparison to free paclitaxel.The preliminary in vivo study demonstrated that tumor uptake of CLR 1602’s paclitaxel payload increased by more than 30-fold over free paclitaxel, and also displayed an extended plasma half-life relative to free paclitaxel. The extended plasma half-life may, in part, explain the enhanced tumor uptake. Unlike free paclitaxel, which was rapidly cleared from plasma within 24 hours,